THERAPY DOSSIER · th-0bf989603e57

5-methoxytryptamine-alpha-lipoic acid (MLA)

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Radiation
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 27314327 ↗2016Reported benefit

The Protective Effects of 5-Methoxytryptamine-alpha-lipoic Acid on Ionizing Radiation-Induced Hematopoietic Injury.

MouseRadiationC57BL/6Male

Model: Ionizing radiation-induced haematopoietic injury following 7.2 Gy total body irradiation

MLA significantly increased survival after 7.2 Gy total body irradiation, increased the number and clonogenic potential of haematopoietic cells, reduced DNA damage measured by histone H2AX phosphorylation, and lowered reactive oxygen species in haematopoietic cells through inhibition of NOX4 expres…

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…